An open label multicenter phase 2 study for the initial evaluation of the tolerability of Birch pollen extract in patients suffering from atopic eczema and clinical relevant IgE-mediated sensitization against birch pollen.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2011
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- 24 Aug 2011 New trial record